文献速递神经肿瘤小儿神经外科与脑积水

DNX-2401治疗儿童新诊断弥漫性内生性桥脑胶质瘤的Ⅰ期试验

Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.
PubMed 文献 · Neurosurgery · 2018-01-01

该Ⅰ期单中心非对照试验旨在评估溶瘤腺病毒DNX-2401经小脑脚注射治疗儿童弥漫性内生性桥脑胶质瘤(DIPG)的安全性、耐受性和毒性,并在活检时采集肿瘤样本。活检后立即注射病毒,2至6周后行标准放化疗。预期改善总生存和生活质量并收集肿瘤标本用于分子分析。

要点

  • DIPG无法手术切除,诊断基于MRI,肿瘤组织标本罕见。
  • Ⅰ期单中心非对照试验:经小脑脚活检后立即注射DNX-2401。
  • 活检后2至6周行标准放化疗,预期改善总生存和生活质量。

核心结论

  • 该试验旨在为DIPG的样本采集做出贡献,并在肿瘤组织活检时使用病毒提供治疗。
  • 若该病毒按预期发挥作用,它 could 杀死肿瘤细胞而不损伤健康组织,起到靶向治疗的作用。
  • 迄今所有试验中均未观察到该病毒引起水肿。

研究设计与样本

  • Ⅰ期、单中心、非对照试验。
  • 经小脑脚进行肿瘤活检,活检后立即注射DNX-2401。
  • 活检后2至6周行由放疗和化疗组成的标准治疗。

主要发现

  • 预期结果为改善DIPG患者的总生存和生活质量,并收集肿瘤标本以研究这些肿瘤的分子特征。
  • 迄今所有试验中均未观察到该病毒引起水肿。

临床怎么用

  • 作者认为,通过该研究及其他类似研究获得的信息可能有助于开发或改进对抗DIPG的新疗法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are no effective treatments for diffuse intrinsic pontine gliomas (DIPGs); these tumors cannot be surgical resected, and diagnosis is based on magnetic resonance imaging. As a result, tumor tissues for molecular studies and pathologic diagnosis are infrequent. New clinical trials are investigating novel medications and therapeutic techniques in an effort to improve treatment of patients with DIPGs. OBJECTIVE: To determine the safety, tolerability, and toxicity of an oncolytic adenovirus, DNX-2401, injected into the cerebellar peduncle in pediatric subjects with DIPG and to collect tumor samples of this type of tumor. METHODS: Phase I, single-center, uncontrolled trial. A tumor biopsy will be performed through the cerebellar peduncle, and DNX-2401 will be injected immediately after the biopsy. Standard therapy consisting of radiotherapy and chemotherapy will follow in 2 to 6 wk. EXPECTED OUTCOMES: Improvement of overall survival and quality of life in patients with DIPG and collection of tumor specimens to study the molecular profiling of these tumors. DISCUSSION: The aims of this trial are to contribute to the sample collection of DIPG and to offer treatment during the tumor tissue biopsy using the virus. If this virus works as expected, it could kill the tumor cells with no damage to healthy tissue, functioning as a targeted therapy. It is important to note that edema has not been observed with this virus in all trials performed to date. The information obtained through this and other similar studies may be useful for developing or improving new therapies in the battle against DIPG.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Tejada S, Alonso M, Patiño A, et al. Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Neurosurgery. 2018. PMID: 29088386. doi:10.1093/neuros/nyx507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。